TOPLINE: Earlier treatment with erenumab was associated with significantly better migraine prevention than that with nonspecific oral migraine preventive medications (OMPMs) in patients with resistant episodic […]

TOPLINE: Discontinuing high-efficacy therapies (HETs) that affect immune cell trafficking such as natalizumab and fingolimod is associated with a significant increased relapse risk in older adults […]

TOPLINE: Receipt of the bivalent COVID-19 vaccine was not associated with an increased stroke risk in the first 6 weeks after vaccination with either the Pfizer […]

TOPLINE: Age-standardized stroke rates decreased in the United States between 1990 and 2019, while absolute stroke incidence, prevalence, mortality, and disability-adjusted life years (DALYs) rates increased, […]

A simple skin biopsy test is able to detect an abnormal form of alpha-synuclein with high accuracy in individuals with neurodegenerative disorders such as Parkinson’s disease […]

The US Food and Drug Administration (FDA) has expanded the indication for the long-acting C5 complement inhibitor, ravulizumab (Ultomiris, Alexion), to include adults with anti–aquaporin-4 (AQP4) […]

The US Food and Drug Administration (FDA) has approved givinostat (Duvyzat) for treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years or older. Givinostat, […]

TOPLINE: Hospitalization for influenza is linked to a greater risk for subsequent neurologic disorders including migraine, stroke, or epilepsy than hospitalization for COVID-19, results of a […]

TOPLINE: Low low-density lipoprotein (LDL) cholesterol is associated with an increased risk of bleeding within 3 months of a major ischemic stroke (MIS) or high-risk transient […]